SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
-9.51%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.44B
AUM Growth
+$1.44B
(-5%)
Cap. Flow
+$114M
Cap. Flow
% of AUM
7.93%
Top 10 Holdings %
Top 10 Hldgs %
59.95%
Holding
66
New
13
Increased
16
Reduced
8
Closed
9
Top Buys
| 1 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$53.7M |
| 2 |
Elanco Animal Health
ELAN
|
$40.6M |
| 3 |
Sanofi
SNY
|
$37.3M |
| 4 |
Kenvue
KVUE
|
$36.2M |
| 5 |
Merck
MRK
|
$20.7M |
Top Sells
| 1 |
Vertex Pharmaceuticals
VRTX
|
$51.1M |
| 2 |
Exelixis
EXEL
|
$37.8M |
| 3 |
Boston Scientific
BSX
|
$32.9M |
| 4 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$32.9M |
| 5 |
AstraZeneca
AZN
|
$22.7M |
Sector Composition
| 1 | Healthcare | 94.38% |
| 2 | Consumer Staples | 2.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
RETA
51
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| – | – |
-322,471
| Closed | -$32.9M |
|
|
CBAY
52
DELISTED
Cymabay Therapeutics
CBAY
| – | – |
0
| – | – |
|
|
53
Vertex Pharmaceuticals
VRTX
$102B
| – | – |
-145,300
| Closed | -$51.1M |
|
54
Vir Biotechnology
VIR
$765M
| – | – |
-488,117
| Closed | -$12M |
|
55
Sarepta Therapeutics
SRPT
$1.98B
| – | – |
0
| – | – |
|
56
SPDR S&P 500 ETF Trust
SPY
$656B
| – | – |
0
| – | – |
|
57
PTC Therapeutics
PTCT
$4.41B
| – | – |
-260,443
| Closed | -$10.6M |
|
58
iShares Russell 2000 ETF
IWM
$66.6B
| – | – |
0
| – | – |
|
59
FibroGen
FGEN
$48.4M
| – | – |
-637,567
| Closed | -$1.72M |
|
60
CRISPR Therapeutics
CRSP
$4.82B
| – | – |
0
| – | – |
|
|
61
Boston Scientific
BSX
$159B
| – | – |
-608,861
| Closed | -$32.9M |
|
62
Baxter International
BAX
$12.1B
| – | – |
-362,200
| Closed | -$16.5M |
|
|
ALLK
63
DELISTED
Allakos
ALLK
| – | – |
-62,465
| Closed | -$272K |
|
64
Revolution Medicines
RVMD
$7.43B
| – | – |
-520,377
| Closed | -$13.9M |
|